Genetic Induction of Phosphate Toxicity Significantly Reduces the Survival of Hypercholesterolemic Obese Mice

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2011 Nov 1

PMID 22037453

Citations 8

Authors

Mutsuko Ohnishi

Shigeko Kato

M Shawkat Razzaque

Affiliations

Soon will be listed here.

Abstract

Objective: The adverse effects of metabolic disorders in obesity have been extensively studied; however, the pathologic effects of hyperphosphatemia or phosphate toxicity in obesity have not been studied in similar depth and detail, chiefly because such an association is thought to be uncommon. Studies have established that the incidence of obesity-associated nephropathy is increasing. Because hyperphosphatemia is a major consequence of renal impairment, this study determines the in vivo effects of hyperphosphatemia in obesity.

Methods And Results: We genetically induced hyperphosphatemia in leptin-deficient obese (ob/ob) mice by generating ob/ob and klotho double knockout [ob/ob-klotho(-/-)] mice. As a control, we made ob/ob mice with hypophosphatemia by generating ob/ob and 1-alpha hydroxylase double knockout [ob/ob-1α(OH)ase(-/-)] mice. Compared to the wild-type mice, all three obese background mice, namely ob/ob, ob/ob-klotho(-/-), and ob/ob-1α(OH)ase(-/-) mice developed hypercholesterolemia. In addition, the hyperphosphatemic, ob/ob-klotho(-/-) genetic background induced generalized tissue atrophy and widespread soft-tissue and vascular calcifications, which led to a shorter lifespan; no such changes were observed in the hypophosphatemic, ob/ob-1α(OH)ase(-/-) mice. Significantly, in contrast to the reduced survival of the ob/ob-klotho(-/-) mice, lowering serum phosphate levels in ob/ob-1α(OH)ase(-/-) mice showed no such compromised survival, despite both mice being hypercholesterolemic.

Conclusion: These genetic manipulation studies suggest phosphate toxicity is an important risk factor in obesity that can adversely affect survival.

Citing Articles

Obesity, Diabetes Mellitus, and Vascular Impediment as Consequences of Excess Processed Food Consumption.

Sinha S, Haque M Cureus. 2022; 14(9):e28762.

PMID: 36105908 PMC: 9441778. DOI: 10.7759/cureus.28762.

Phosphate Burden and Inflammation.

Erem A, Osuka S, Razzaque M Adv Exp Med Biol. 2022; 1362:7-13.

PMID: 35288868 DOI: 10.1007/978-3-030-91623-7_2.

Salivary phosphate as a biomarker for human diseases.

Razzaque M FASEB Bioadv. 2022; 4(2):102-108.

PMID: 35141474 PMC: 8814558. DOI: 10.1096/fba.2021-00104.

Dietary phosphate toxicity: an emerging global health concern.

Erem S, Razzaque M Histochem Cell Biol. 2018; 150(6):711-719.

PMID: 30159784 DOI: 10.1007/s00418-018-1711-8.

Can salivary phosphate levels be an early biomarker to monitor the evolvement of obesity?.

Hartman M, Groppo F, Ohnishi M, Goodson J, Hasturk H, Tavares M Contrib Nephrol. 2013; 180:138-48.

PMID: 23652556 PMC: 3896993. DOI: 10.1159/000346793.

References

Fox C, Larson M, Leip E, Culleton B, Wilson P, Levy D . Predictors of new-onset kidney disease in a community-based population. JAMA. 2004; 291(7):844-50. DOI: 10.1001/jama.291.7.844. View

Zha Y, Le V, Higami Y, Shimokawa I, Taguchi T, Razzaque M . Life-long suppression of growth hormone-insulin-like growth factor I activity in genetically altered rats could prevent age-related renal damage. Endocrinology. 2006; 147(12):5690-8. DOI: 10.1210/en.2006-0302. View

Praga M, Morales E . Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006; 15(5):481-6. DOI: 10.1097/01.mnh.0000242172.06459.7c. View

Razzaque M . Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2010; 120(3):91-7. PMC: 3120105. DOI: 10.1042/CS20100377. View

Ohnishi M, Kato S, Akiyoshi J, Atfi A, Razzaque M . Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J. 2011; 25(6):2031-9. PMC: 3101030. DOI: 10.1096/fj.10-167056. View

Tanaka M, Yamada S, Iwasaki Y, Sugishita T, Yonemoto S, Tsukamoto T . Impact of obesity on IgA nephropathy: comparative ultrastructural study between obese and non-obese patients. Nephron Clin Pract. 2009; 112(2):c71-8. DOI: 10.1159/000213084. View

Ohnishi M, Nakatani T, Lanske B, Razzaque M . Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 2009; 75(11):1166-1172. PMC: 3143194. DOI: 10.1038/ki.2009.24. View

Warnke R, Kempson R . The nephrotic syndrome in massive obesity: a study by light, immunofluorescence, and electron microscopy. Arch Pathol Lab Med. 1978; 102(8):431-8. View

Lanske B, Razzaque M . Premature aging in klotho mutant mice: cause or consequence?. Ageing Res Rev. 2007; 6(1):73-9. PMC: 2896497. DOI: 10.1016/j.arr.2007.02.002. View

10.

Kato S, Nazneen A, Nakashima Y, Razzaque M, Nishino T, Furusu A . Pathological influence of obesity on renal structural changes in chronic kidney disease. Clin Exp Nephrol. 2009; 13(4):332-340. DOI: 10.1007/s10157-009-0169-3. View

11.

Razzaque M . Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life. 2011; 63(4):240-7. PMC: 3120048. DOI: 10.1002/iub.437. View

12.

Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y . Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol. 2003; 17(12):2393-403. DOI: 10.1210/me.2003-0048. View

13.

Ohnishi M, Razzaque M . Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010; 24(9):3562-71. PMC: 2923352. DOI: 10.1096/fj.09-152488. View

14.

Potluri K, Hou S . Obesity in kidney transplant recipients and candidates. Am J Kidney Dis. 2010; 56(1):143-56. DOI: 10.1053/j.ajkd.2010.01.017. View

15.

Razzaque M, Taguchi T . Collagen-binding heat shock protein (HSP) 47 expression in anti-thymocyte serum (ATS)-induced glomerulonephritis. J Pathol. 1997; 183(1):24-9. DOI: 10.1002/(SICI)1096-9896(199709)183:1<24::AID-PATH1106>3.0.CO;2-B. View

16.

Tsuboi N, Kawamura T, Ishii T, Hosoya T . Obesity-related nephropathy associated with a history of IgA nephropathy. Intern Med. 2008; 47(19):1713-8. DOI: 10.2169/internalmedicine.47.1196. View

17.

Fukagawa M, Hamada Y, Nakanishi S, Tanaka M . The kidney and bone metabolism: Nephrologists' point of view. J Bone Miner Metab. 2006; 24(6):434-8. DOI: 10.1007/s00774-006-0719-7. View

18.

Razzaque M . The dualistic role of vitamin D in vascular calcifications. Kidney Int. 2010; 79(7):708-14. PMC: 3120050. DOI: 10.1038/ki.2010.432. View

19.

Pausova Z . From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens. 2006; 15(2):173-8. DOI: 10.1097/01.mnh.0000214775.42103.a5. View

20.

Mathew A, Okada S, Sharma K . Obesity related kidney disease. Curr Diabetes Rev. 2010; 7(1):41-9. DOI: 10.2174/157339911794273928. View